Lunai Bioworks 10-K: Less Than One Month of Cash, Going Concern Warning, Nasdaq Equity Deficit
LNAI sits 19% above its 52-week low of $0.876 on light trading volume (0.2× avg).
Summary
Lunai Bioworks disclosed less than one month of cash runway, a going concern warning, a material weakness, and a Nasdaq equity deficit in its fiscal 2026 annual report.
Key Events · Earnings and Guidance · LNAI
-
Going Concern Warning
Auditor Sadler, Gibb & Associates issued an explanatory paragraph stating substantial doubt about the company's ability to continue as a going concern. As of October 13, 2026, the company has less than one month of available cash resources.
-
Cash Runway Critical
Cash and cash equivalents were $1,713,653 as of June 30, 2026, with a working capital deficit of $16,874,093. The company states it does not have sufficient cash to fund near-term operations without additional financing.
-
Nasdaq Equity Deficit
Stockholders' deficit of $9,024,946 as of June 30, 2026 is below Nasdaq's $2,500,000 minimum equity requirement. The company is subject to a one-year Mandatory Panel Monitor and could face delisting if it fails the bid price rule again.
-
Material Weakness in ICFR
Management concluded internal control over financial reporting was not effective as of June 30, 2026 due to inadequate resources to address complex accounting matters.
Analysis · LNAI · Life Sciences
Lunai Bioworks' annual report reveals the company has less than one month of cash runway as of October 13, 2026, a going concern warning from its auditor, a material weakness in internal controls, and a stockholders' deficit of $9.0 million that violates Nasdaq's minimum equity requirement. The company is actively pursuing financing but has no assurance it will succeed. The Series B Preferred Stock carries a $20.0 million liquidation preference that would consume all remaining equity in a liquidation, and full conversion would dilute existing holders by approximately 36%. This filing establishes the financial baseline for a company that may be weeks away from insolvency.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 45.8% of the 251 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.67%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNAI was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.88 to $13.28. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.